Skip to main content
رجوع
RARE logo

Ultragenyx Pharmaceutical Inc.

جودة البيانات: 100%
RARE
NASDAQ Healthcare Biotechnology
KWD 20.27
▲ KWD 0.40 (2.01%)
القيمة السوقية: 1.96B
نطاق اليوم
KWD 19.53 KWD 20.33
نطاق 52 أسبوعًا
KWD 18.41 KWD 42.37
حجم التداول
2,031,847
متوسط 50 يوم / 200 يوم
KWD 22.84 / KWD 29.64
الإغلاق السابق
KWD 19.87

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -3.4 0.4
P/B 2.9
ROE % -656.0 3.8
Net Margin % -85.4 3.9
Rev Growth 5Y % 17.6 10.0
D/E 0.2

النقاط الرئيسية

Revenue grew 17.64% annually over 5 years — strong growth
Negative free cash flow of -472.00M
PEG of 0.54 suggests growth is underpriced
Capital efficient — spends only 0.89% of revenue on capex

النمو

Revenue Growth (5Y)
17.64%
Revenue (1Y)20.13%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-656.03%
ROIC-33.55%
Net Margin-85.44%
Op. Margin-79.49%

الأمان

Debt / Equity
N/A
Current Ratio2.48
Interest Coverage-8.63

التقييم

P/E Ratio
-3.41
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20.13% Revenue Growth (3Y) 24.49%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 17.64% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 673.00M Net Income (TTM) -575.00M
ROE -656.03% ROA -37.53%
Gross Margin 83.80% Operating Margin -79.49%
Net Margin -85.44% Free Cash Flow (TTM) -472.00M
ROIC -33.55% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.48
Interest Coverage -8.63 Dividend Yield 0.00%
Valuation
P/E Ratio -3.41 P/B Ratio N/A
P/S Ratio 2.91 PEG Ratio 0.54
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.96B Enterprise Value 2.80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 673.00M 560.23M 434.25M 363.33M 351.41M
Net Income -575.00M -569.18M -606.64M -707.42M -454.03M
EPS (Diluted) -5.83 -6.29 -8.25 -10.12 -6.70
Gross Profit 564.00M 483.50M 389.04M 335.01M 335.40M
Operating Income -535.00M -535.97M -569.21M -648.92M -381.74M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.53B 1.50B 1.49B 1.55B 1.52B
Total Liabilities 1.61B 1.24B 1.22B 1.19B 599.84M
Shareholders' Equity -80.00M 255.30M 275.41M 352.49M 922.56M
Total Debt 1.28B 40.34M 43.17M 31.59M 41.97M
Cash & Equivalents 434.00M 173.73M 213.58M 132.94M 307.58M
Current Assets 951.00M 817.12M 732.18M 883.90M 856.60M
Current Liabilities 384.00M 344.15M 280.44M 261.21M 181.37M